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Background: Many methodologies have been used in research to identify the “intrinsic” subtypes of breast cancer
commonly known as Luminal A, Luminal B, HER2-Enriched (HER2-E) and Basal-like. The PAM50 gene set is often
used for gene expression-based subtyping; however, surrogate subtyping using panels of immunohistochemical
(IHC) markers are still widely used clinically. Discrepancies between these methods may lead to different treatment
decisions.
Methods: We used the PAM50 RT-qPCR assay to expression profile 814 tumors from the GEICAM/9906 phase III
clinical trial that enrolled women with locally advanced primary invasive breast cancer. All samples were scored at a
single site by IHC for estrogen receptor (ER), progesterone receptor (PR), and Her2/neu (HER2) protein expression.
Equivocal HER2 cases were confirmed by chromogenic in situ hybridization (CISH). Single gene scores by IHC/CISH
were compared with RT-qPCR continuous gene expression values and “intrinsic” subtype assignment by the PAM50.
High, medium, and low expression for ESR1, PGR, ERBB2, and proliferation were selected using quartile cut-points
from the continuous RT-qPCR data across the PAM50 subtype assignments.
Results: ESR1, PGR, and ERBB2 gene expression had high agreement with established binary IHC cut-points (area
under the curve (AUC)≥ 0.9). Estrogen receptor positivity by IHC was strongly associated with Luminal (A and B)
subtypes (92%), but only 75% of ER negative tumors were classified into the HER2-E and Basal-like subtypes.
Luminal A tumors more frequently expressed PR than Luminal B (94% vs 74%) and Luminal A tumors were less
likely to have high proliferation (11% vs 77%). Seventy-seven percent (30/39) of ER-/HER2+ tumors by IHC were
classified as the HER2-E subtype. Triple negative tumors were mainly comprised of Basal-like (57%) and HER2-E
(30%) subtypes. Single gene scoring for ESR1, PGR, and ERBB2 was more prognostic than the corresponding IHC
markers as shown in a multivariate analysis.
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Conclusions: The standard immunohistochemical panel for breast cancer (ER, PR, and HER2) does not adequately
identify the PAM50 gene expression subtypes. Although there is high agreement between biomarker scoring by
protein immunohistochemistry and gene expression, the gene expression determinations for ESR1 and ERBB2 status
was more prognostic.Background
For over a decade, research studies have used gene expres-
sion to classify invasive breast cancers into biologically and
clinically distinct subtypes that have become known as
Luminal A, Luminal B, HER2-Enriched (HER2-E) and
Basal-like [1-3]. Subtype information has repeatedly shown
to be an independent predictor of survival in breast cancer
when used in multivariate analyses with standard clinical-
pathological variables [3-6]. In 2009, Parker et al. derived a
minimal gene set (PAM50) for classifying “intrinsic”
subtypes of breast cancer [3,7]. The PAM50 gene set has
high agreement in classification with larger “intrinsic”
gene sets previously used for subtyping [1,3,4,8], and is
now commonly employed [9-12].
There are several multi-gene expression tests clinically
available for determining risk of relapse in early stage
breast cancer, including the 21-gene recurrence score
[13] (Oncotype DxW, Genomic Health Inc, Redwood City,
CA, www.oncotypedx.com), the 14-gene distant metastasis
signature [14] (BreastOncPx™, US Labs, Irvine, CA,
www.uslabs.net), the 97-gene histologic grade predictor
[15] (MapQuant Dx™ Genomic Grade, Ipsogen, Marseilles,
France and New Haven, CT, USA, www.ipsogen.com), and
the 70-gene prognosis signature [16] (MammaPrintW,
Agendia, Irvine, CA, www.agendia.com). The molecu-
lar signature of proliferation is perhaps the strongest
variable in all these tests for determining outcome in
ER + breast cancer.
In addition to gene expression profiling by micro-
array or RT-qPCR [2-4,8,17,18], many studies have
used immunohistochemical panels to identify subtypes
[19-21]. For example, high grade ER+/HER2- tumors
and ER+/HER2+ tumors are often considered Luminal
B, while ER-/HER2+ are considered HER2-E subtype
and triple negative tumors are considered Basal-like. In
this study, we assess agreement between histopathology/
IHC status and PAM50 classification for subtype, ESR1,
PGR, ERBB2, and proliferation.Methods
Samples and clinical data
There was ethical review and approval for all protocols
used in this study from the respective centers involved
and all subjects gave written informed consent to par-
ticipate. A training set was developed using 171 breast
samples, comprised of 16 “normal” breast tissue samplesfrom reduction mammoplasties or grossly uninvolved
breast tissue and 155 primary invasive breast cancers.
These samples were collected from 2005–2009 under
IRB approved protocols at the University of Utah and
the University of North Carolina at Chapel Hill. Clinical-
pathological information associated with the samples is
based on the College of American Pathology (CAP) and
American Joint Committee on Cancer (AJCC) standards
at the time of collection (Additional file 1). Subtype classifi-
cation and single and meta-gene (proliferation) scores
were predicted on an independent test set of 814 sam-
ples from the GEICAM/9906 clinical trial, a rando-
mized Phase 3 trial of fluorouracil, epirubicin, and
cyclophosphamide alone or followed by paclitaxel
[22]. Patients that were hormone receptor positive
(ER and/or PR positive by IHC) were given adjuvant
tamoxifen. The hormone receptor status for these
samples was evaluated at a single site (Department of
Pathology, Hospital General Universitario de Alicante)
using immunohistochemistry (IHC) for progesterone
receptor (PR) (clone PgR636, DAKO, Glostrup, Den-
mark) and estrogen receptor (ER) (clone 1D5, DAKO,
Glostrup, Denmark) (Additional file 2). The scores for
the proportion of dyed cells and intensity were summed to
obtain a total Allred Score [23]. Measurement of HER2 ex-
pression was performed by Herceptest™ (DAKO, Glostrup,
Denmark) and samples with scores of 2+ by IHC were
confirmed by CISH, following the ASCO/CAP guide-
lines [24]. The clinical data for the training set and
GEICAM/9906 test set are summarized in Table 1.Measurement of PCR efficiency, limits of detection, and
limits of quantification
Breast cancer cell lines (BT474, MCF7, MDA-MB-231,
MDA-MB-436, MDA-MB-453, MDA-MB-468, SKBR3
and T47D) were cultured, pelleted and processed into
FFPE tissue blocks. The RNA was extracted, pooled, re-
verse transcribed, and serially diluted at 2-fold increments
from 2.56μg to 0.039ng per assay, which corresponds to a
range of 7.11ng to 108.51fg of cDNA per reaction well.
Each gene was measured in triplicate per RT-qPCR
run on the Roche LC480 and 2 runs were performed
for each of the 17 dilutions. A detailed description of
methods used to calculate PCR efficiency, limits of de-
tection and limits of quantification can be found in
Additional file 3.
Table 1 Patient characteristics
Variable Training set data n = 154 Total (%) Variable Test set data n = 814 Total (%)
Age (years) Median 55.5 Age (years) Median 50.4
(range) 26 – >92 (range) 23.1 – 76.2
Menopausal status Pre 49 (31.8) Menopausal status Pre 439 (53.9)
Post 101 (65.6) Post 375 (46.1)
Unknown 4 (2.6)
Primary tumor size T1 63 (40.9) Primary tumor size T1 338 (41.5)
T2 69 (44.8) T2 430 (52.8)
T3 17 (11.0) T3 46 (5.7)
Unknown 1 (0.6)
Reduction Mamoplasty 4 (2.6)
Nodal status 0 95 (61.7) Nodal status 0 0
1 – 3 54 (35.1) 1 – 3 503 (61.8)
> 3 0 (0) > 3 311 (38.2)
Unknown 1 (0.6)
Reduction Mamoplasty 4 (2.6)
Histopathologic grade* G1 23 (14.9) Histopathologic grade* G1 107 (13.1)
G2 45 (29.2) G2 335 (41.2)
G3 80 (51.9) G3 313 (38.5)
GX 2 (1.3) GX 59 (7.2)
Reduction Mamoplasty 4 (2.6)
Estrogen receptor^ Positive 100 (64.9) Estrogen receptor^ Positive 644 (79.1)
Negative 49 (31.8) Negative 170 (20.9)
Unknown 1 (0.6)
Reduction Mamoplasty 4 (2.6)
Progesterone receptor^^ Positive 82 (53.2) Progesterone receptor^^ Positive 567 (69.7)
Negative 67 (43.5) Negative 247 (30.3)
Unknown 1 (0.6)
Reduction Mamoplasty 4 (2.6)
HER2 status Positive 37 (24.0) HER2 status Positive 116 (14.3)
Negative 111 (72.1) Negative 698 (85.7)
Unknown 2 (1.3)
Reduction Mamoplasty 4 (2.6)
Ki67 IHC Unknown 154 (100) Ki67 IHC Positive 236 (29.6)
Negative 561 (70.4)
PAM50 Intrinsic Subtype Luminal A 53 (34.4) PAM50 Intrinsic Subtype Luminal A 277 (34.0)
Luminal B 27 (17.5) Luminal B 261 (32.1)
HER2-enriched 32 (20.8) HER2-enriched 174 (21.4)
Basal-like 38 (24.7) Basal-like 70 (8.6)
Normal-like 4 (2.6) Normal-like 32 (3.9)
*Grade based on Nottingham-Bloom-Richardson scoring.
^ER positive required at least 10% staining nuclei.
^^PR positive required at least 10% staining nuclei.
#HER2 positive were 3+ IHC or 2+ and CISH confirmed.
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set
Training set samples were run across 3 batches of PCR
plates manufactured at ARUP Laboratories (ARUP Labora-
tories, Salt Lake City, UT, www.aruplab.com). The method
to identify prototype samples representing the subtypes has
been previously described [3]. Briefly, hierarchical clustering
(median centered by gene, Pearson correlation, centroid-
linkage) [25] was performed on the RT-qPCR data and Sig-
Clust was run at each node of the dendrogram beginning at
the root and stopping when the test was no longer signifi-
cant (p> 0.001). A “centroid” was generated for each sub-
type in the training set using the average expression for
each gene across all prototype samples of a given subtype.
Single sample subtype prediction was performed by
calculating a Spearman rank correlation coefficient
between the gene expression values of an individual
sample compared to each of the centroid gene values
for Luminal A, Luminal B, HER2-Enriched, Basal-like,
and Normal. The subtype classification for the new
sample is assigned to the centroid with the highest
correlation.
10-Fold cross validation to determine stability of selected
prototypes
The 154 prototype samples identified by SigClust were
randomly split into 10 groups. Nine of the 10 groups
were used to calculate new centroids for each of the 5
possible subtype assignments. Each sample from the
remaining group was then assigned a subtype based
on closest proximity to the newly calculated cen-
troids using Spearman's Rho. The process of calculat-
ing centroids using 9 of the 10 groups and predicting
on the remaining group was repeated leaving out a
different group each time.
Measurements of assay reproducibility
Reproducibility of the PAM50 assay was determined
using 3 cell lines (MCF7, ME16C and SKBR3) and a
pool of Luminal A prototype samples that were each run
12 times (3 runs across 4 batches of PAM50 plates) over
30 days. Variation in each gene measurement was
assessed using the difference between the mean calibrator
crossing point (CP) and each sample replicate CP (ΔCP).
The square root of the mean CV2 for ΔCP was used to es-
timate the variation for each gene within plate, within
batch, and across batches. Higher gene CVs may be due to
lower concentration of a single gene within a sample. We
used the technical variability in measuring each gene to
further assess the stability of the categorical subtype call in
the GEICAM/9906 test set samples. Since the biology be-
tween subtypes is a continuum and some samples may
have close proximity to more than 1 prototypic sub-
type, we used a Monte-Carlo simulation to introducerandom error into the call to determine the frequency
of switching subtype [26].
Scaling single and Meta-Gene scores
The PAM50 subtype assay can also provide quantitative
and qualitative gene expression scores for the standard
biomarkers usually measured semi-quantitatively by
IHC: ESR1/ER, PGR/PR and ERBB2/HER2. In addition,
the PAM50 contains many cell cycle regulated genes that
can be combined into a meta-gene for proliferation
(CENPF, ANLN, CDC20, CCNB1, CEP55, MYBL2, MKI67,
UBE2C, RRM2, and KIF2C). The meta-gene for prolif-
eration were selected because they had strong correl-
ation within the associated dendrogram of the training
set cluster. The quantitative scale of 1–10 for the single
genes and proliferation was derived by rescaling the
original log-expression ratios from the training set and
included a 10% buffer on either side of the original
values to allow for values that were higher or lower
than what was encountered in the training set. Any
new values that were less than 0 or greater than 10
were truncated at 0 and 10, respectively.
Fixed cut-points (low vs. intermediate/high) for the
single genes (ESR1, PGR, and ERBB2) and proliferation
were directly applied from the training set to the GEI-
CAM/9906 test set. Receiver Operator Characteristic
(ROC) curves were generated by dichotomizing IHC data
and treating RT-qPCR data as a continuous variable.
Results
Training set, subtype stability, and classification
accuracy
We identified 154 prototypic samples from the RT-
qPCR data by hierarchical clustering of the PAM50 clas-
sifier genes, and statistical selection from the dendro-
gram by SigClust [27]. The training set was comprised
of 53 Luminal A, 27 Luminal B, 32 HER2-enriched, 38
Basal-like and 4 Normal-like (Figure 1). The 10-fold
cross validation had 91.6% concordance (multi-rater
kappa score of 0.885) with the initial SigClust subtype
assignments (Additional file 4).
Interference from normal breast tissue contamination
A major source of subtype misclassification comes from
having normal tissue within the tumor sample [28].
We assessed the effect of having contaminating normal
tissue within the tumor sample by diluting out RNA
from tumor subtypes with pooled RNA from “normal”
reduction mammoplasties (0%, 25%, 50% and 75%).
Primary tumors were pooled to represent Luminal A
and HER2-E samples while cell lines were used to
represent Luminal B (MCF7) and Basal-like (ME16C).
The changes in subtype classification occurred in a
systematic fashion with all subtypes switching directly
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Figure 1 Clinical PAM50 RT-qPCR breast cancer training set. Hierarchical clustering of RT-qPCR data for the PAM50 classifier genes
normalized to the 5 control genes using 171 FFPE procured breast samples. Statistical selection using SigClust identified the 5 significant groups
previously identified and designated as Luminal A (dark blue), Luminal B (light blue), HER2-E (pink), Basal-like (red), and Normal (green). The 16
non-neoplastic samples (grey), from reduction mammoplasty and grossly uninvolved breast tissues, all Clustered together and away from the
invasive cancers. SigClust identified 4 reduction mammoplasty samples (green) that were used to train the Normal subtype.
Table 2 Cut-points for quantitative gene scores
Score ranges
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Luminal B, which switched to Luminal A. The switch
from Luminal B to Luminal A required 50% contribu-
tion from the normal breast tissue signature. Interfer-
ence data from the introduction of normal breast
tissue RNA into each of the subtypes is provided in
Additional file 5. During the dilution series for HER2-E
with “normal” there was switching in the ESR1 score
between intermediate and low suggesting that both
samples had similar ESR1 expression near the cut-off
for those scores.Genes/Meta-genes Low Intermediate High
ESR1 (ER)† 0 - 5.2 >5.2 - 7.6 >7.6 - 10
PGR (PR){ 0 - 5.1 >5.1 - 7.4 >7.4 - 10
ERBB2 (HER2)} 0 - 5.6 >5.6 - 7.5 >7.5 - 10
Proliferation* 0 - 3.9 >3.9 - 5.3 >5.3 - 10
†high ESR1 = above median expression for Luminal A; low ESR1=below
median expression for HER2-enriched.
{high PGR= above median expression for Luminal A; low PGR=below median
expression for Luminal B.
}high ERBB2= above median expression for HER2-enriched; low ERBB2=below
lowest quartile expression for HER2-enriched.
*high Proliferation = above highest quartile expression for Luminal A; low
Proliferation = below lowest quartile expression for Luminal A.Subtype, immunohistochemistry, and RT-qPCR gene
scores
The RT-qPCR values for ESR1, PGR, ERBB2, and prolif-
eration were evaluated across prototypic samples in the
training set. High, intermediate, and low cut points were
made based on the continuous distribution of expression
across the tumor subtypes. The cut-points for each of
the scores and how they were determined is presented
in Table 2. Figure 2 shows the expression and cut-points
for ESR1 in the training set and how these comparewithin the GEICAM/9906 test set. Additional single and
meta-gene cut-points for the training and test sets can
be found in Additional file 6. Comparisons between the
gene expression and IHC data for GEICAM/9906 gave
good overall agreement with a high area under the curve
(AUC) for ESR1/ER (AUC= 0.90), PGR/PR (AUC=0.90),
and ERBB2/HER2 (AUC= 0.95) (Figure 3). Rather than
re-optimize the cut-points on the test set, the fixed cut-
Figure 2 ESR1 score cut-offs using training set and the GEICAM/9906 testing set. The ESR1 score is provided as a qualitative call of high,
intermediate, or low. The cut-offs were based on the continuous expression of ESR1 across prototype samples in the training set. Each circle on the
box plot represents an individual sample that is color coded according to IHC status. The cut-points between high, intermediate, and low classes were
individually derived from the training set samples (A). Data from ESR1 gene expression over the GEICAM 9906 samples (B) are plotted on the same
scale as the training set. Samples are colored according to ER IHC positivity (red) or negativity (blue) determined at a central facility.
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high sensitivity/specificity, although a slightly higher
false positive rate for ERBB2 than would have been
selected by eye.
Ninety-two percent (497/538) of Luminal (A/B)
tumors were ER+ by IHC and 99% (530/538) had an
intermediate-high ESR1 score (Tables 3 and 4). Luminal
A tumors more frequently expressed PR/PGR than
Luminal B tumors using either IHC (94% vs 74%) or
qPCR (95% vs 61%).False po
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Figure 3 Receiver Operator Characteristic (ROC) curves for ESR1, PGR,
GEICAM/9906 test set were generated using the clinical IHC status (positive
RT-qPCR data for ESR1, PGR, and ERBB2. The cut-points for sensitivity/specifiAlthough the HER2-E subtype is often thought of as
being ER-, only 36% (63/174) were ER- by IHC and 44%
(76/174) were low ESR1 score. Seventeen percent of
HER2-E samples were called triple-negative. Of the
clinically HER2+ group by IHC/CISH, approximately
two-thirds (69/113 = 61%) were HER2-E and one-third
were Luminal B (37/113= 33%) subtype (Figure 4). Using
the qPCR cut-off for ERBB2 expression, we found that
98% (609/624) of samples that were low ERBB2 were also
HER2- by IHC/CISH, while 53% (109/190) of tumors withsitive rate
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and ERBB2 for the GEICAM/9906 test set. ROC curves for the
vs. negative) for ER, PR, and HER2/neu as compared to the continuous
city are based on the training set.
Table 3 Histological scoring across PAM50 subtypes
Grade ER PR HER2
LumA G1-68 (25%) Neg-19 (7%) Neg-16 (6%) Neg-273 (99%)
n=277 G2-142 (51%) Pos-258 (93%) Pos-261 (94%) Pos-4 (1%)
G3-39 (14%)
GX-28 (10%)
LumB G1-25 (10%) Neg-22 (8%) Neg-68 (26%) Neg-224 (86%)
n=261 G2-111 (43%) Pos-239 (92%) Pos-193 (74%) Pos-37 (14%)
G3-111 (43%)
GX-14 (5%)
HER2-E G1-6 (3%) Neg-63 (36%) Neg-93 (53%) Neg-105 (60%)
n=174 G2-65 (37%) Pos-111 (64%) Pos-81 (47%) Pos-69 (40%)
G3-96 (55%)
GX-7 (4%)
Basal G1-0 (0%) Neg-63 (90%) Neg-62 (89%) Neg-67 (96%)
n= 70 G2-4 (6%) Pos-7 (10%) Pos-8 (11%) Pos-3 (4%)
G3-61 (87%)
GX-5 (7%)
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ever, analyses just within the HER2-E subtype showed 71%
(66/93) of tumors with high ERBB2 gene expression were
HER2+ by IHC/CISH.
Ninety percent (63/70) of Basal-like tumors were ER-
by IHC and 96% (67/70) were low ESR1 score. Further-
more, 81% (57/70) of Basal-like tumors were triple nega-
tive (ER-/PR-/HER2-) by IHC/CISH and 86% (60/70)Table 4 Single gene scores and proliferation across
PAM50 subtypes
Proliferation ESR1^ PGR^ ERBB2^
LumA Low-104 (38%) Neg-0 (0%) Neg-15 (5%) Neg-254
(92%)
n=277 Intermediate-116
(42%)
Pos-277
(100%)
Pos-262
(95%)
Pos-23 (8%)
High-57 (11%)
LumB Low-4 (2%) Neg-8 (3%) Neg-101
(39%)
Neg-194
(74%)
n=261 Intermediate-55
(21%)
Pos-253
(97%)
Pos-160
(61%)
Pos-67
(26%)
High-202 (77%)
HER2-
E
Low-15 (9%) Neg-76
(44%)
Neg-112
(64%)
Neg-81
(47%)
n=174 Intermediate-60
(34%)
Pos-98 (56%) Pos-62
(36%)
Pos-93
(53%)
High-99 (57%)
Basal Low-0 (0%) Neg-67
(96%)
Neg-67
(96%)
Neg-66
(94%)
n= 70 Intermediate-3 (4%) Pos-3 (4%) Pos-3 (4%) Pos-4 (6%)
High-67 (96%)
^ RT-qPCR status based on intermediate-high (positive) versus low (negative).were low in all 3 genes by qPCR (Table 5). Conversely,
only 56% (57/101) and 67% (60/90) of triple negatives
defined by IHC/CISH or qPCR were Basal-like, respect-
ively. There was no difference (p > 0.05) in ESR1, PGR or
ERBB2 expression by qPCR in Basal-like tumors, regard-
less of being triple-negative or non-triple negative by
IHC/CISH (Figure 5).
Additional file 7 shows a comparison of unsupervised
hierarchical clustering with supervised subtype assign-
ment and single marker scores for GEICAM/9906. In
general, the supervised classification agreed with the
sample associated dendrogram clusters. The side branches
of the dendrogram clusters are less correlated to other
samples and reflect the continuum in the biology, espe-
cially between Luminal A, Luminal B and HER2-E sub-
types. The HER2-E and Basal-like subtypes cluster
away from the Luminal tumors and have similar gene
expression profiles overall; however, standard IHC/
CISH biomarkers poorly define these subtypes.
Prognostic significance of gene expression versus
standard methods for ER and HER2 status
Although there was high agreement between IHC/CISH
and RT-qPCR measurements for ER/ESR1 and HER2/
ERBB2, we wanted to assess whether the two different
methods provided equivalent prognostic information.
When tested in a multivariate Cox model for overall sur-
vival, only the RT-qPCR assignments were selected in
the final Cox model in the GEICAM/9906 test set
(Table 6). When all patients with locally advanced breast
cancer were stratified, regardless of chemotherapy regimen
(FEC vs FEC-T), both classifications for assessing ER/ESR1
and HER2/ERBB2 status were significantly associated with
outcome (Figure 6). Since endocrine therapy was based on
ER status determined by IHC, those ER + samples that
were ESR1- (29/154= 19%) would have received adjuvant
tamoxifen and conversely those patients with ER- tumors
that were ESR1+ (45/660 =7%) would not have received
therapy. When separating outcome based on agreement
and disagreement between the methods, we find that
women with ER+/ESR1+ tumors have similar outcomes
to women with ER-/ESR1+ tumors, and women with
ER-/ESR1- tumors have similar outcomes to women
with ER+/ESR1- tumors. This shows that the RT-qPCR
assignment is more prognostic and accurate than IHC
for ER.
Discussion
Many studies have tried to identify the gene expression-
based “intrinsic” subtypes using a variety of methods for
the sake of simplicity, cost, and available technologies.
Methods that can be used from formalin-fixed, paraffin-
embedded tissues are optimal since this is how samples
are procured and archived in most pathology departments.
Figure 4 Association between HER2 status and “intrinsic” subtype. Figure (A) shows the subtype distribution within HER2+ samples by IHC/
CISH. Figure (B) shows the ER/HER2 status for samples only within the HER2-E subtype.
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ing from FFPE tissues are RT-qPCR [17,18] and Nano-
string nCounter [29]. The nCounter system uses color-
coded probes that bind directly to the RNA transcript
without reverse transcription and PCR amplification.
While these methods have high agreement for gene
quantification, other methodologies may lead to differ-
ent conclusions and treatment decisions. For instance,
in the NCIC.CTG MA.12 clinical trial that randomized
pre-menopausal women with primary breast cancer to
tamoxifen versus placebo it was found that a panel 6
IHC antibodies for subtyping was not prognostic butTable 5 Surrogate subtyping by 3-marker scoring
Luminal A Luminal B HER2-E Basal-
like
ER+/PR+/HER2- (n = 471) 244 (52%) 170 (36%) 53 (11%) 4 (1%)
ESR1+/PGR+/ERBB2-
(n = 397)
239 (60%) 127 (32%) 31 (8%) 0 (0%)
ER+/PR-/HER2- (n = 81) 12 (15%) 47 (58%) 19 (23%) 3 (4%)
ESR1+/PGR-/ERBB2-
(n = 101)
15 (15%) 65 (64%) 18 (18%) 3 (3%)
ER-/PR-/HER2+ (n = 39) 0 (0%) 7 (18%) 30 (77%) 2 (5%)
ESR1-/PGR-/ERBB2+
(n = 51)
0 (0%) 6 (12%) 41 (80%) 4 (8%)
ER-/PR-/HER2- (n = 101) 4 (4%) 10 (10%) 30 (30%) 57
(56%)
ESR1-/PGR-/ERBB2- (n = 90) 0 (0%) 2 (2%) 28 (31%) 60
(67%)
ER+/PR+/HER2+ (n = 45) 2 (4%) 18 (40%) 25 (56%) 0 (0%)
ESR1+/PGR+/ERBB2+
(n = 80)
23 (29%) 33 (41%) 24 (30% 0 (0%)
ER+/PR-/HER2+ (n = 18) 0 (0%) 4 (22%) 14 (78%) 0 (0%)
ESR1+/PGR-/ERBB2+
(n = 53)
0 (0%) 28 (53%) 25 (47%) 0 (0%)
ER-/PR+/HER2- (n = 25) 14 (56%) 4 (16%) 3 (12%) 4 (16%)
ESR1-/PGR+/ERBB2- (n = 7) 0 (0%) 0 (0%) 4 (57%) 3 (43%)
ER-/PR+/HER2+ (n = 2) 1 (50%) 1 (50%) 0 (0%) 0 (0%)
ESR1-/PGR+/ERBB2+
(n = 3)
0 (0%) 0 (0%) 3 (100%) 0 (0%)the PAM50 RT-qPCR subtypes were prognostic [30]. In
another randomized study (NCIC.CTG MA.5) that
assessed PAM50 subtype sensitivity to anthracycline-
based chemotherapy, it was shown that the HER2-E
subtype received the most benefit, while women with
Basal-like tumors had no benefit from this aggressive
treatment [31]. This study and the MA.5 trial found that
only about two-thirds of clinically Her2+ tumors are
classified as HER2-E and about the same percent of
triple negatives are classified as Basal-like. Thus, only a
subset of the IHC defined groups overlap with PAM50
subtype classification, which may have ramifications for
clinical trial findings and predicting therapy benefit.
Receiver Operator Characteristic (ROC) curves are
commonly used in medicine to optimize the sensitivity/
specificity of an assay depending on the purpose of the
test (i.e. screening, monitoring, prognosis, etc.) [32]. In
clinical pathology, ROC curves are often used to validate
a new methodology against an existing “gold” standard.
A major limitation to this approach is that cut-offs are
then determined by comparison to an often less than
perfect reference. We used an approach for selecting
single (ESR1, PGR, ERBB2) and meta-gene (prolifera-
tion) cut-offs that was based on the distribution of
expression of these markers across the different sub-
types. This method showed to be reproducible in an
independent test set.
The ROC curves showed high agreement between RT-
qPCR and the standard IHC biomarkers. ESR1 had high
sensitivity although the cut-off for ER+ status was 10%
positive staining nuclei, whereas the new recommendation
for determining ER status is 1% [33]. These borderline
cases for ER positivity may be better characterized by the
overall subtype biology. For ERBB2, there was high
specificity, which is optimal since confirmatory CISH
or FISH would only be performed when it was un-
certain if the gene was truly amplified [34]. It has
been suggested that the use of single gene RT-qPCR
measurement for ERBB2 is insufficient for determin-
ing HER2 positive samples that may benefit from
trastuzumab/HerceptinW therapy [35]. Dabbs et al.
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0
2
4
6
8
10 p=0.24
nonTNBC TNBC
0
2
4
6
8
10 p=0.572
nonTNBC TNBC
0
2
4
6
8
10 p=0.168
nonTNBC TNBC
Figure 5 Relative transcript abundance for ESR1, PGR, and ERBB2 in the Basal-like subtype. There was no difference (p > 0.05) in (A) ESR1,
(B) PGR, or (C) ERBB2 expression by qPCR in Basal-like tumors, regardless of being called triple-negative or non-triple negative by IHC/CISH.
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http://www.biomedcentral.com/1755-8794/5/44found that the negative predictive value for determin-
ing HER2/ERBB2 status was high between the Her-
cepTest and the GHI Oncotype Dx qPCR assay
(99%); but the concordance for positive HER2/ERBB2
samples was only 28%. In contrast, we showed that
the concordance between HER2 (IHC/CISH) and
ERBB2 (RT-qPCR) is greater than 90% when
restricted to the HER2-E subtype.
In order to determine if there was a prognostic dif-
ference between the RT-qPCR and IHC we included
both methods in a Cox proportional hazards model
and showed that gene expression remained significant
in the multivariate analysis and replaced IHC. Fur-
thermore, the outcome plots for women with tumors
scored positive for ER by IHC but negative for ESR1
had outcomes similar to women that were ER-/ESR1-.
Conversely, women with ER- tumors by IHC but
positive for ESR1 had similar outcomes to women
with ER+/ESR1+ disease. Thus, despite the fact that
patients were treated in favor of the IHC diagnosis
(i.e. ER + disease was treated with adjuvant tamoxifen)
the course of disease was in agreement with the gene
expression determination. The better prognosis seen
in the ESR1+ but ER- subtype is curious since these
patients would not have been given adjuvantTable 6 Univariate and multivariate analyses of prognostic fa
MVA analysis for OS Univariate analysis
Signatures HR Lower 95% Upper 95% p-value
ARM FEC-P vs. FEC 0.708 0.528 0.948 0.021
Grade 3 vs. 1-2 1.745 1.297 2.346 <0.001
Nodes >3 vs. 1-3 2.103 1.574 2.808 <0.001
Tumor size >2 cm vs. ≤2cm 2.089 1.510 2.890 <0.001
Age >50 vs ≤50 1.189 0.890 1.589 0.242
ER status by IHC+ vs. - 0.619 0.449 0.855 0.004
ER status by GE + vs. - 0.536 0.387 0.741 <0.001
Clinical HER2 status + vs. - 1.389 0.9532 2.024 0.0872endocrine blockade therapy. However, gene expression
for ESR1 may be identifying the “true” luminal origin
of these tumors which have a better prognosis, re-
gardless of therapy [30]. In addition, the patients
included in the test set were locally advanced and
received chemotherapy that can cause chemotherapy
induced amenorrhea and a reduction in ovarian func-
tion [36], which again may benefit the luminal sub-
type most.
The Normal subtype was developed from reduction
mammoplasty “normal” breast tissue and serves as a
quality control measure since these cases would be con-
sidered to have an insufficient amount of tumor tissue
to make a tumor subtype call. Interference studies
showed that the introduction of “normal” breast tissue
RNA caused a systematic shift in subtype assignment
with subtypes switching to Normal, except Luminal B
which changed to Luminal A.
None of the assignment switches occurred until the
introduction of 50% “normal” breast tissue RNA. The
greatest risk of misclassification would come from Lu-
minal B subtypes masquerading as Luminal A tumors
because of “normal” tissue contamination [28]; however,
these tumors maintain a high proliferation score sug-
gesting they are still a high risk Luminal tumor.ctors in GEICAM/9906
Multivariate analysis (backward/forward stepwise selection)
HR Lower 95% Upper 95% p-value
0.734 0.543 0.993 0.045
1.335 0.962 1.853 0.084
1.882 1.391 2.546 0.000
1.724 1.224 2.427 0.002
1.012 0.999 1.026 0.078
- - - -
0.630 0.438 0.906 0.013
- - - -
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Figure 6 Kaplan-Meier plots of overall survival in GEICAM 9906 data set. When stratifying all patients with locally advanced breast cancer,
regardless of chemotherapy regimen (FEC vs FEC-T), both RT-qPCR (A) and IHC/CISH (B) molecular classifications for assessing ESR1/ER and ERBB2/
Her2 status were significant. However, the separation of the survival curves suggests that ER-status as assessed by qPCR has prognostic superiority
to IHC (C).
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http://www.biomedcentral.com/1755-8794/5/44A fifth tumor type that has often been referred to
as “Normal-like” has been suggested to be an artifact
of having too few tumor cells and a large background
of normal breast cells in the sample. Our mixing
experiments here support this hypothesis and show
that when increasing amounts of “normal” tissue
RNA is added to a tumor it switches into the
Normal-like group. It is, however, suspected that
some tumors now called Normal-like may be put into
the recently described Claudin-low classification [37].
The Claudin-low subtype is mostly triple-negative,
shares biomarkers in common with normal breast
epithelial cells and Basal-like tumors, and may be
caused by deficiency in either BRCA1or p53, or both;
however there is no clinical indication for Claudin-
low, and most are typically classified as Basal-like.
There are now many more groups of tumors being
identified with transcriptome and copy number vari-
ance analyses [38,39]. The overlap between these new
groups, existing subtypes, and standard biomarkers
already in practice should allow for more personalized
treatments and better outcomes in the future.Conclusions
Compiling small biomarker panels for the purpose of
“intrinsic” subtyping is of limited value in identifying
PAM50 based subtypes. Gene expression scoring for
ESR1 and ERBB2 has good agreement with the corre-
sponding protein biomarkers (ER and HER2) and may
have more prognostic power.Additional files
Additional file 1: Clinical-pathological information associated with
training set subtypes. Clinical-pathological information associated with
the 171 samples included in the training set.
Additional file 2: Clinical-pathological information and PAM50 data
associated with GEICAM/9906 test set. Clinical-pathological
information and PAM50 RT-qPCR results associated with the 814 samples
included in the GEICAM9906 test set.
Additional file 3: Additional materials and methods. Methods for
plate manufacturing, PCR, calculation of log-expression ratios, PCR-
efficiency, limits of detection, and limits of quantification are described
(Additional files 8 and 9).
Additional file 4: 10-fold cross validation of training set. Each gene
was measured in triplicate per RT-qPCR run on the Roche LC480 and 2
runs were performed for each of the 17 dilutions. The prototype samples
identified by SigClust were split into 10 groups and nine of the 10
groups were used to calculate new centroids for each of the 5 possible
subtype assignments.
Additional file 5: Interference in subtype call and single/meta-gene
scores from normal contamination. Interference by normal cell
contamination of subtype call and single and meta-gene classes is shown.
The changes in subtype classification occurred in a systematic fashion with
all subtypes switching to a classification of Normal/Insufficient, with the
exception of Luminal B, which switched to Luminal A.
Additional file 6: Single and meta-gene cutoffs. Data from single and
meta-gene expression score over the GEICAM 9906 samples are plotted
on the 1–10 scale. The cut-points between high, intermediate, and low
classes were individually derived from the training set. Samples are color-
coded according to immunohistochemistry positivity (red) or negativity
(blue), except in the case of the training set proliferation score where
samples are colored by high, intermediate or low proliferation class.
Luminal score samples are colored as being ER+/PR+, ER + or
PR + (positive, red), and ER-/PR- (negative, blue).
Additional file 7: Hierarchical clustering for GEICAM 9906. A
comparison of unsupervised hierarchical clustering with supervised
subtype assignment and single marker scores for GEICAM 9906.
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http://www.biomedcentral.com/1755-8794/5/44Additional file 8: PCR Efficiency, limits of detection, and limits of
quantification. Supplemental table listing the efficiency of PCR, limits of
detection, and limits of quantification for the 50 classifier and 5
housekeeper genes of the PAM50. Data are from 34 runs across 17
dilutions from a mixture of 8 breast cancer cell lines.
Additional file 9: Reproducibility of PAM50 gene measurements.
Within plate, within plate batch and across plate batch coefficient of
variation for the 50 classifier and 5 housekeeper genes of the PAM50
were calculated using cell lines and a tumor samples.
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